PA
ACOR

Profund Advisors’s Acorda Therapeutics ACOR Stock Holding History

Profund Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-71
Closed -$244K – 1583
2018
Q2 		$244K Buy
+71
New +$217K 0.01% 1303
2017
Q2 		– Sell
-83
Closed -$209K – 1492
2017
Q1 		$209K Sell
83
-35
-30% -$101K 0.01% 1362
2016
Q4 		$265K Buy
+118
New +$281K 0.01% 1298
2016
Q1 		– Sell
-69
Closed -$356K – 1490
2015
Q4 		$356K Buy
+69
New +$302K 0.02% 839
2015
Q3 		– Sell
-76
Closed -$303K – 1394
2015
Q2 		$303K Sell
76
-16
-17% -$61.8K 0.01% 1113
2015
Q1 		$366K Buy
92
+32
+53% +$147K 0.01% 1117
2014
Q4 		$292K Buy
60
+7
+13% +$30K 0.01% 1144
2014
Q3 		$216K Sell
53
-230
-81% -$863K 0.01% 1187
2014
Q2 		$1.15M Sell
283
-50
-15% -$204K 0.05% 411
2014
Q1 		$1.51M Buy
333
+19
+6% +$76.8K 0.07% 270
2013
Q4 		$1.1M Buy
314
+74
+31% +$289K 0.05% 461
2013
Q3 		$986K Buy
240
+14
+6% +$60.3K 0.05% 446
2013
Q2 		$896K Buy
+226
New +$930K 0.06% 317

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Profund Advisors's ACOR Position: Q3 2018 in Review

Profund Advisors sold out of Acorda Therapeutics (ACOR) in Q3 2018, closing a stake of 71 shares — an estimated $244K sold.

Profund Advisors first reported a position in ACOR in Q2 2013 and held it in 13 quarters. The position peaked at $1.51M in Q1 2014. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2018.

  • Profund Advisors reported no remaining Acorda Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Profund Advisors sold 71 Acorda Therapeutics shares in Q3 2018, an estimated $244K.
  • Profund Advisors first reported a position in Acorda Therapeutics in Q2 2013 and held it in 13 quarters.
  • Profund Advisors's Acorda Therapeutics position peaked at $1.51M in Q1 2014.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2018.

Based on Profund Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.